The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass.
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Fibrinogen (Primary)
- Indications Postoperative haemorrhage
- Focus Therapeutic Use
- Acronyms RiaSTAP
- 05 Apr 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 05 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 03 Jan 2017 Status changed from not yet recruiting to recruiting.